481 related articles for article (PubMed ID: 35216204)
1. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma.
Kitamura F; Miyata T; Uemura N; Uchihara T; Imai K; Hayashi H; Yamashita YI; Matsusaki K; Ishimoto T; Baba H
Anticancer Res; 2021 Jun; 41(6):2895-2900. PubMed ID: 34083280
[TBL] [Abstract][Full Text] [Related]
3. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
6. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.
Satoh M; Takano S; Sogawa K; Noda K; Yoshitomi H; Ishibashi M; Mogushi K; Takizawa H; Otsuka M; Shimizu H; Miyazaki M; Nomura F
Cancer Sci; 2017 Apr; 108(4):795-803. PubMed ID: 28161904
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead.
Kim H; Park J; Wang JI; Kim Y
Expert Rev Proteomics; 2017 Nov; 14(11):963-971. PubMed ID: 28926720
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Yang RB; Xia YL; Zhou HC; Wu W; Lu Y; Hu LW; Zhao Y
Med Oncol; 2013; 30(2):583. PubMed ID: 23609192
[TBL] [Abstract][Full Text] [Related]
9. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics.
Kou YQ; Yang YP; Pan ZJ; Du SS; Yuan WN; He K; Nie B
Med Sci Monit; 2023 Mar; 29():e938785. PubMed ID: 36905103
[TBL] [Abstract][Full Text] [Related]
10. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
11. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
[TBL] [Abstract][Full Text] [Related]
12. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
13. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
15. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
18. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients.
Xie ZB; Yao L; Jin C; Zhang YF; Fu DL
Eur J Surg Oncol; 2019 Feb; 45(2):207-212. PubMed ID: 30389300
[TBL] [Abstract][Full Text] [Related]
19. Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):1017-1019. PubMed ID: 35179767
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]